Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

The Lancet (Impact Factor: 39.21). 09/1981; 2(8241):270-1. DOI: 10.1016/S0140-6736(81)90523-7
Source: PubMed

ABSTRACT This study is a double-blind controlled trial in 86 patients of the efficacy of retention enemas containing 4 g 5-aminosalicylic acid (5-ASA), believed to be the active metabolite of sulphasalazine, compared with retention enemas of 100 mg of hydrocortisone for the topical treatment of mild or moderate ulcerative colitis. 5-ASA enemas given to 44 patients were significantly more effective than hydrocortisone enemas given to 42 patients, and produced 93, 93, and 77% remission in clinical, sigmoidoscopic, and histological terms, respectively, compared with corresponding remission rates of 57, 54, and 33% in the hydrocortisone treated patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The local and systemic bioavailability of a mesalazine enema (Pentasa®, Ferring A/S, Denmark) and a mesalazine suppository (Pentasa®, Ferring) was assessed during steady-state conditions. Eleven healthy subjects took 1 g of the enema or the suppository twice daily for 1 week, with a drug-free period of at least 1 week in between. At the end of each treatment period the urine and faeces were collected for 48 h, and the concentrations of mesalazine and the metabolite acetyl-mesalazine were measured. Plasma concentrations of drug and metabolite were measured hourly during a 12-h dose interval. The faecal water concentration of mesalazine was significantly higher after suppository treatment (55.7 mmol/1) compared with enema treatment (31.7 mmol/1) (p
    Scandinavian Journal of Gastroenterology. 07/2009; 26(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent decades, the prominent role of endoscopy in the management of ulcerative colitis (UC) has been translated into the concept of mucosal healing (MH) as a fundamental therapeutic end-point. This is partially the consequence of growing evidence of a positive prognostic role of MH on the disease course and partially due to market cues indicating a higher rate of MH in patients treated by novel potent biologic agents. The aim of the present review is to clarify the current knowledge of MH in UC, analyzing the definition, the putative prognostic role and the association of MH with the current drugs used to treat UC patients. Because solid data about the management of UC patients based solely on the healing of the mucosa are not yet available, a tailored approach for individual patients thatconsiders the natural history of UC and the presence of prognostic indicators of aggressive disease is desirable. Consequently, unnecessary examinations and treatment would be avoided and restricted to UC patients who require the maximum amount of effort to affect the disease course in the short and long term.
    World journal of gastrointestinal pathophysiology. 05/2014; 5(2):54-62.
  • Source
    Journal of Clinical Pharmacy and Therapeutics 06/1983; 8(3). · 2.10 Impact Factor